Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://link.springer.com/doi/10.1007/s002130100742 below:

The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors

Rationale: The benzazepine and "selective" dopamine D₁ receptor antagonist, SCH23390 [(R)-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-benzazepine-7-ol], shows significant affinity at native serotonin (5-HT)_2C receptors. Objectives: We examined its functional actions at cloned human (h)5-HT_2C receptors (VSV isoform) stably expressed in CHO cells. Methods: Since 5-HT_2C receptors are positively coupled to phospholipase C (PLC), their activation was determined by depletion of membrane-bound pools of pre-labelled [³H]phosphotidylinositol ([³H]PI). Results: SCH23390 showed high affinity (K_i, 9.3 nM) at h5-HT_2C sites and depleted [³H]PI with an EC₅₀ of 2.6 nM. Its efficacy was equivalent to that of 5-HT. [³H]PI depletion elicited by SCH23390 was concentration-dependently abolished by the selective 5-HT_2C antagonist, SB242,084, with a K_B of 0.55 nM. Further, in the presence of a fixed concentration of SB242,084 (10 nM), the concentration-response curve for SCH23390 was shifted to the right without loss of maximal effect, yielding a K_B of 0.57 nM. Conclusions: SCH23390 is a potent and high efficacy agonist at h5-HT_2C receptors. Activation of 5-HT_2C receptors by SCH23390 may contribute to its functional properties both in animals and in humans.

This is a preview of subscription content, log in via an institution to check access.

Springer+ Basic

€34.99 /Month

• Get 10 units per month
• Download Article/Chapter or eBook
• 1 Unit = 1 Article or 1 Chapter
• Cancel anytime

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

1. Institut de Recherches Servier, Psychopharmacology Department, 125, Chemin de Ronde, 78290-Croissy/Seine, Paris, France, , , , ,

   Mark J. Millan, Adrian Newman-Tancredi, Yann Quentric & Didier Cussac

1. Mark J. Millan
2. Adrian Newman-Tancredi
3. Yann Quentric
4. Didier Cussac

Electronic Publication

Millan, M.J., Newman-Tancredi, A., Quentric, Y. et al. The "selective" dopamine D₁ receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin_2C receptors. Psychopharmacology 156, 58–62 (2001). https://doi.org/10.1007/s002130100742

Download citation

• Received: 13 August 2000

• Accepted: 15 February 2001

• Issue Date: June 2001

• DOI: https://doi.org/10.1007/s002130100742

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.4